POZ - Treatment News : Guidelines Panel Leaves Abacavir Recommendations Unchanged

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2008

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


email print

April 7, 2008

Guidelines Panel Leaves Abacavir Recommendations Unchanged

The expert panel that produces the Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents has issued a communication indicating that abacavir (found in ZiagenEpzicom and Trizivir) should remain a preferred drug for use in people who are starting HIV treatment for the first time.

Abacavir was moved from “alternative” to “preferred” when the guidelines were last updated in January 2008. Subsequently, a study was published showing an increased risk of heart attacks in people taking abacavir, and a group of patients in a second study were unblinded and told what medications they were taking, because of an increased number of treatment failures in a group of people taking abacavir who had viral loads over 100,000 before starting treatment.

In response to these two studies, the guidelines panel issued a statement that concluded, “At this point, the Panel concludes that the preliminary information available from these studies does not warrant a change in its current recommendations regarding the use of antiretroviral drugs in adults and adolescents. The Panel will continue to review additional data as they become available and will make further recommendations if needed. Meanwhile, the Panel recommends clinicians consider all available information so that the optimal therapeutic choice for each patient is based on individual patient characteristics and the potential risks and benefits of each treatment component.”


Scroll down to comment on this story.

email print

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

         


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar
Starting Treatment
Quilt in the Capital
POZ Army


    dambitious
    Baltimore Co.
    Maryland


    Reginaldb06
    los angeles
    California


    sefarady
    Los Angeles
    California


    ZanderPetros
    San Jose
    California
Click here to join POZ Personals!
Talk to Us
Poll
Do you support rapid in-home HIV testing?
Yes
No

Survey
Health 2.0

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.